Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase 3 1

Status

Recruiting 5Completed 4Withdrawn 2Terminated 2Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Glioma 2Recurrence 1Leukemia, Myeloid, Acute 1IDH1 Mutation Myeloid Neoplasms 1Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Completed × ivosidenib × Clear all
NCT02073994 2026-02-17

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Servier

Phase 1 Completed
174 enrolled
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

NCT03343197 2026-02-17

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Servier

Phase 1 Completed
49 enrolled
CNS

Glioma

NCT03564821 2025-11-04

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Massachusetts General Hospital

Phase 1 Completed
18 enrolled
Myeloid

IDH1 Mutation Myeloid Neoplasms

NCT04176393 2023-02-13

A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation

CStone Pharmaceuticals

Phase 1 Completed
30 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡